Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…
-
EMA approval · 2026-08-18EMA Authorised: Tagrisso (osimertinib mesilate) — AstraZeneca AB
Authorised status for Tagrisso (osimertinib mesilate) by EMA for non-small cell lung cancer, marking regulatory approval in the European Uni…
-
FDA approval · 2026-08-14FDA Approved: ALECENSA — Supplemental Application (Genentech, Inc.)
Supplemental application for Alecensa (alectinib hydrobromide) submitted by Genentech, Inc. for regulatory action related to an approved ind…
-
EMA approval · 2026-07-21EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
Roche's Tecentriq (atezolizumab) has been authorised by the EMA for multiple indications including transitional cell carcinoma, non-small ce…
-
EMA approval · 2026-07-16EMA Authorised: Rybrevant (amivantamab) — Janssen-Cilag International N.V.
EMA authorises Rybrevant (amivantamab) for non-small cell lung carcinoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-03EMA Authorised: Retsevmo (selpercatinib) — Eli Lilly Nederland B.V.
Authorization of Retsevmo (selpercatinib) by EMA for use in non-small cell lung cancer and thyroid neoplasms.
-
EMA approval · 2026-07-03EMA Authorised: Cejemly (sugemalimab) — Cstone Pharmaceuticals Ireland Limited
EMA has authorised Cejemly (sugemalimab) for non-small cell lung carcinoma, with Cstone Pharmaceuticals Ireland Limited as the marketing aut…
-
EMA approval · 2026-07-03EMA Authorised: Lorviqua (Lorlatinib) — Pfizer Europe MA EEIG
Lorviqua (lorlatinib) has been authorised for use in Europe for non-small cell lung carcinoma.
-
EMA approval · 2026-07-01EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
EMA authorises Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin disease, renal cell carcinoma, non-smal…
-
EMA approval · 2026-06-10EMA Authorised: Vargatef (nintedanib) — Boehringer Ingelheim International GmbH
Approval of Vargatef (nintedanib) by EMA for non-small cell lung carcinoma.
-
EMA approval · 2026-06-08EMA Authorised: Alecensa (alectinib hydrochloride) — Roche Registration GmbH
The EMA authorised Alecensa (alectinib hydrochloride) for non-small cell lung carcinoma, with Roche Registration GmbH as the MAH.
-
EMA approval · 2026-04-22EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, ren…
-
EMA approval · 2026-04-17EMA Authorised: Tepmetko (tepotinib hydrochloride monohydrate) — Merck Europe B.V.
The European Medicines Agency authorised Tepmetko (tepotinib hydrochloride monohydrate) for use in non-small cell lung cancer, with Merck Eu…
-
EMA approval · 2026-04-15EMA Authorised: Lorviqua (Lorlatinib) — Pfizer Europe MA EEIG
The EMA authorised Lorviqua (lorlatinib) for use in non-small cell lung cancer. The decision confirms EU approval of the product for this in…
-
EMA approval · 2026-03-31EMA Authorised: Alecensa (alectinib hydrochloride) — Roche Registration GmbH
The European Medicines Agency authorised Alecensa (alectinib hydrochloride) for treatment of non-small cell lung cancer under Roche Registra…
-
EMA approval · 2026-03-30EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
The European Medicines Agency authorized Tecentriq (atezolizumab) by Roche Registration GmbH for multiple cancer indications, including non-…
-
EMA approval · 2026-03-26EMA Authorised: Lazcluze (lazertinib mesilate monohydrate) — Janssen Cilag International NV
The European Medicines Agency authorised Lazcluze (lazertinib mesilate monohydrate) for non-small cell lung cancer, with Janssen Cilag Inter…
-
EMA approval · 2026-03-25EMA Authorised: Zirabev (bevacizumab) — Pfizer Europe MA EEIG
Zirabev (bevacizumab) has been authorised by EMA for multiple cancer indications, including colorectal, breast, non-small cell lung, renal c…
-
EMA approval · 2026-03-19EMA Authorised: Vargatef (nintedanib) — Boehringer Ingelheim International GmbH
EMA authorised Vargatef (nintedanib) by Boehringer Ingelheim International GmbH for the treatment of non-small cell lung cancer in the Europ…
-
EMA approval · 2026-03-19EMA Authorised: Imfinzi (durvalumab) — AstraZeneca AB
The European Medicines Agency has authorised Imfinzi (durvalumab) for non-small cell lung cancer. AstraZeneca AB is the marketing authorizat…
-
EMA approval · 2026-02-27EMA Authorised: Aumseqa (Aumolertinib mesilate) — SFL Pharmaceuticals Deutschland GmbH
The EMA authorised Aumseqa (aumolertinib mesilate) for non-small cell lung cancer, marking EU approval for this EGFR inhibitor with SFL Phar…
-
EMA approval · 2026-02-18EMA Authorised: Cejemly (sugemalimab) — Cstone Pharmaceuticals Ireland Limited
EMA has authorised Cejemly (sugemalimab) for non-small cell lung cancer.
-
FDA approval · 2026-02-13FDA Approved: RYBREVANT FASPRO — Original Application (Janssen Biotech, Inc.)
FDA approved the original biologics license for Rybrevant Faspro, a subcutaneous formulation of amivantamab with hyaluronidase-lpuj, develop…
-
EMA approval · 2026-02-12EMA Authorised: Retsevmo (selpercatinib) — Eli Lilly Nederland B.V.
The European Medicines Agency authorised Retsevmo (selpercatinib) for RET fusion-positive cancers in the EU, including non-small cell lung c…
-
EMA approval · 2026-02-11EMA Authorised: Imjudo (tremelimumab) — AstraZeneca AB
EMA has authorised Imjudo (tremelimumab) from AstraZeneca AB for hepatocellular carcinoma and non-small cell lung cancer.